Microbiota: a novel regulator of pain

Defaye, Manon; Gervason, Sandie; Altier, Christophe; Berthon, Jean‐Yves; Ardid, Denis; Filaire, Edith; Carvalho, Frédéric A.

doi:10.1007/s00702-019-02083-z

Cited by 55 publications

(55 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have also been conducted to assess whether targeting pathways associated with gut microbiota might be a way to overcome CIPN [158]. Probiotics show therapeutic effects in various diseases, such as travelers' diarrhea or irritable bowel syndrome, and previous studies have also confirmed their protective role in various nociceptive pain states [159][160][161], but, at present, little is known about their potential effect on CIPN.…”

Section: Future Outlook: Data From Preclinical Studiesmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Sałat

2020

Pharmacol. Rep

View full text Add to dashboard Cite

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the most common dose-limiting adverse effects of several chemotherapeutic agents, such as platinum derivatives (oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib. CIPN affects more than 60% of patients receiving anticancer therapy and although it is a nonfatal condition, it significantly worsens patients' quality of life. The number of analgesic drugs used to relieve pain symptoms in CIPN is very limited and their efficacy in CIPN is significantly lower than that observed in other neuropathic pain types. Importantly, there are currently no recommended options for effective prevention of CIPN, and strong evidence for the utility and clinical efficacy of some previously tested preventive therapies is still limited. Methods The present article is the second one in the two-part series of review articles focused on CIPN. It summarizes the most recent advances in the field of studies on CIPN caused by oxaliplatin, the third-generation platinum-based antitumor drug used to treat colorectal cancer. Pharmacological properties of oxaliplatin, genetic, molecular and clinical features of oxaliplatin-induced neuropathy are discussed. Results Available therapies, as well as results from clinical trials assessing drug candidates for the prevention of oxaliplatininduced neuropathy are summarized. Conclusion Emerging novel chemical structures-potential future preventative pharmacotherapies for CIPN caused by oxaliplatin are reported.

show abstract

Section: Future Outlook: Data From Preclinical Studiesmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Sałat

2020

Pharmacol. Rep

View full text Add to dashboard Cite

show abstract

“…Currently, the relationship between gut microbiota and pain modulation has attracted more and more clinicians’ attention along with the advancement of medical science. A growing body of research showed that bacteria could activate nociceptors directly via their products and constitutive elements [ 5 ]. During infection, bacterial formyl peptides induce calcium flux and action potentials in nociceptor neurons and thereby result in mechanical pain sensitivity in mice [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, α-hemolysin, one of the pore-forming toxins secreted by Staphylococcus aureus , could induce neuronal firing and spontaneous pain [ 7 , 8 ]. Interestingly, previous studies indicated that nociceptor neurons could especially recognize bacterial constitutive/secreted molecules, which are partly involved in the pain signaling [ 5 , 9 ]. Besides, viral and fungal pathogens are identified to elicit alteration of pain sensitivity via inducing immune activation [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy

et al. 2020

View full text Add to dashboard Cite

Neuropathic pain (NP) is a sustained and nonreversible condition characterized by long-term devastating physical and psychological damage. Therefore, it is urgent to identify an effective treatment for NP. Unfortunately, the precise pathogenesis of NP has not been elucidated. Currently, the microbiota-gut-brain axis has drawn increasing attention, and the emerging role of gut microbiota is investigated in numerous diseases including NP. Gut microbiota is considered as a pivotal regulator in immune, neural, endocrine, and metabolic signaling pathways, which participates in forming a complex network to affect the development of NP directly or indirectly. In this review, we conclude the current understanding of preclinical and clinical findings regarding the role of gut microbiota in NP and provide a novel therapeutic method for pain relief by medication and dietary interventions.

show abstract

“…Butyrate, on the other hand, is generated by bacteria of the phylum Firmicutes (83). Data is accumulating to demonstrate that the gut microbiota influences the perception of pain (84); that it can influence the pathogenesis of Alzheimer's disease (85)(86)(87), Parkinson's disease (88), and some psychiatric disorders (89), such as attention deficit hyperactivity disorder (90) and autism spectrum disorder (91); and that it can be associated with problems of cognitive impairment (92). The relationship between various health problems and activation of the microbiota-gut-brain axis is schematically presented in Fig.…”

Section: Discussionmentioning

confidence: 99%

Microbiota-Gut-Brain Signaling: A Minireview

Kubelková¹,

Macela²

2020

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

The gut microbiota of vertebrates, including humans, constitutes an integral genomic part that, together with the genome of the host, may be included under the umbrella concept of hologenome, which itself can be seen as one of the possible tools for evolution. Present-day lifestyles, technologically processed nutrients, and various diseases impact significantly upon composition of the intestinal microbiota. Knowledge recently brought to light has shown the gut microbiota to be a component of the microbiota-gut-brain axis having feedback effects on physiological and psychological processes of the host organism and its health. This minireview summarizes current knowledge and opinions on the importance of the microbiota-gut-brain axis and discusses possibilities for beneficially modulating one of the organism's most vital axes.

show abstract

Microbiota: a novel regulator of pain

Cited by 55 publications

References 219 publications

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy

Microbiota-Gut-Brain Signaling: A Minireview

Contact Info

Product

Resources

About